慢性腎臟病與高尿酸血症之研究進展

10.6666/ClinMed.201905_83(5).0051

沈佳霖

無症狀高尿酸血症（asymptomatic hyperuricemia） ； 慢性腎臟病（chronic kidney disease） ； 末期腎臟病（end stage renal disease） ； 血液透析（hemodialysis）

臨床醫學月刊

83卷5期（2019 / 05 / 31）

309 - 313

繁體中文

高尿酸血症的發生率逐年在攀升，我們對於高尿酸血症的認知也逐年在改變。近年來學界持續發表研究以釐清有關高尿酸血症在慢性腎臟病致病機轉中的角色。大型流行病學觀察型研究已證實尿酸本身即為慢性腎臟病惡化之獨立因子。高尿酸血症一般引起的共病症為痛風，尿路結石或尿酸腎病變。對於並未引起共併症之無症狀高尿酸血症（asymptomatic hyperuricemia）治療時機與對象目前仍未有具體共識。此外，高尿酸血症在已接受血液透析治療之末期腎臟病患者，近年來認定有不同的臨床意義。目前論文顯示治療高尿酸血症可延緩慢性腎臟病疾病進程。從腎臟學角度來看，慢性腎臟病患應針對可能受益者積極介入無症狀高尿酸血症的治療，以防止腎功能惡化。

1. Bellomo, G,Venanzi, S,Verdura, C(2010).Association of uric acid with change in kidney function in healthy normotensive individuals.Am J Kidney Dis,56,264-272.
2. Chang, YH,Lei, CC,Lin, KC(2016).Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study.Diabetes Metab Res Rev,32,557-564.
3. Chen, D-Y,Lee, I-T,Lin, S-C(2016).Taiwan guideline for the management of gout and hyperuricemia-updated 2016.Formosan Journal of Rheumatology,30,1-32.
4. Feig, DI,Soletsky, B,Johnson, RJ(2008).Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.JAMA,300,924-932.
5. Goicoechea, M,deVinuesa, SG,Verdalles, U(2010).Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.Clin J Am Soc Nephrol,5,1388-1393.
6. Grayson, PC,Kim, SY,LaValley, M(2011).Hyperuricemia and incident hypertension: a systematic review and meta-analysis.Arthritis Care Res,63,102-110.
7. Horie, S,Ito, S,Okada, H(2014).Japanese guidelines of the management of hematuria 2013.Clin Exp Nephrol,18,679-689.
8. Jalal, DI(2016).Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.Curr Med Res Opin,32,1863-1869.
9. Jalal, DI,Chonchol, M,Chen, W(2013).Uric acid as a target of therapy in CKD.Am J Kidney Dis,61,134-146.
10. Kang,DH,Nakagawa, T,Feng, L(2002).A role for uric acid in the progression of renal disease.J Am Soc Nephrol,13,2888-2897.
11. Kanji, T,Gandhi, M,Clase, CM(2015).Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.BMC Nephrol,16,58.
12. Khanna, D,Fitzgerald, JD,Khanna, PP(2012).2012 American College of Rheumatology guidelines for management of gout. Part1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.Arthritis Care Res,64,1431-1446.
13. Madero, M,Sarnak, MJ,Wang, X(2009).Uric acid and long-term outcomes in CKD.Am J Kidney Dis,53,796-803.
14. Mazzali, M,Hughes, J,Kim, YG(2001).Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.Hypertension,38,1101-1106.
15. Miao, Y,Ottenbros, SA,Laverman, GD(2011).Effect of a reduction in uric acid on renal outcomes during losartaN treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.Hypertension,58,2-7.
16. Obermayr, RP,Temml, C,Gutjahr, G(2008).Elevated uric acid increases the risk for kidney disease.J Am Soc Nephrol,19,2407-2413.
17. Park, C,Obi, Y,Streja, E(2017).Serum uric acid, protein intake and mortality in hemodialysis patients.Nephrol Dial Transplant,32,1750-1757.
18. Paul, BJ,Anoopkumar, K,Krishnan, V(2017).Asymptomatic hyperuricemia: is it time to intervene?.Clin Rheumatol,36,2637-2644.
19. Sircar, D,Chatterjee, S,Waikhom, R(2015).Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.Am J Kidney Dis,66,945-950.
20. Weiner, DE,Tighiouart, H,Elsayed, EF(2008).Uric acid and incident kidney disease in the community.J Am Soc Nephrol,19,1204-1211.